Posted On: 24 Dec 2025
Sydney, Australia, 24 December 2025 - HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Dr Chris Baldwin as Chief Executive Officer and Managing Director, effective 5 January 2026.
Dr Baldwin brings more than two decades of experience spanning scientific research, operational leadership, capital markets and commercial strategy across Australia, Asia-Pacific, Europe and the United States. He holds a PhD in Chemical Engineering from the University of Cambridge, for which he was selected as British Marshall Scholar, and began his career in academia as an Associate Professor of Chemical Engineering at Iowa State University. Dr Baldwin subsequently transitioned into industry, joining McKinsey & Company in New York. His subsequent roles have spanned C-suite and founder positions across ASX-listed and international biotechnology and precision therapeutics companies.
Dr Baldwin has led corporate and capital strategy, investor engagement, new market entry, partnership formation and product launches for healthcare and high-tech organisations. He also brings extensive experience managing Asia-Pacific P&L portfolios with leading medical device companies, Terumo BCT and Haemonetics.
Executive Chairman, Dr John Cullity commented, “On behalf of the Board, I am pleased to welcome Dr Chris Baldwin as CEO and Managing Director of HaemaLogiX. Chris brings a rare combination of deep scientific expertise and global commercial leadership, with a proven track record across global healthcare, biotechnology and technology-led organisations. As we move into 2026, the Board is confident that Chris’ execution-focused leadership will strengthen the Company’s foundations and
position HaemaLogiX to deliver on our clinical, commercial and corporate objectives. Of course, key amongst these is our planned IPO.”
Commenting on his appointment, Dr Chris Baldwin said, “HaemaLogiX has built a compelling immunotherapy platform with the potential to address significant unmet needs for patients with blood cancers. I am excited to join the Company at this important stage of growth and to work with the Board and team to advance our clinical programs, build strategic partnerships and create long-term value for patients and investors.”